Syntropharma advances transdermal drug patch with $2.4m
This article was originally published in Clinica
Executive Summary
Syntropharma is looking to complete development of its skin patch treatment for depression after securing £1.25m ($2.4m) in its second fundraising round. The transdermal patch will deliver reformulated Selegiline, an off-patent monamine oxidase inhibitor primarily indicated for depression, but which also has applications in Parkinson's disease. Newton St Boswells, Scottish Borders-based Syntropharma expects to submit trial data of the product to the US FDA by Q2 2009, with view of a product launch in 2010. The financing will also be used to advance its pipeline products, which include a drug patch for treating delusional psychosis and another for managing alcohol and opioid addictions. Investors in Syntropharma include Scottish Enterprise, Highland Venture Capital, LINC, Chimaera Bio and TRI Cap.
Register for our free email digests: